Advertisement

Advertisement

PRLD Stock Latest News

H.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly

The FlyH.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly

Prelude enters clinical trial collaboration, supply agreement with Eli Lilly

PremiumThe Fly

Prelude enters clinical trial collaboration, supply agreement with Eli Lilly

8d ago

Prelude Therapeutics initiated with an Overweight at JPMorgan

PremiumThe Fly

Prelude Therapeutics initiated with an Overweight at JPMorgan

1M ago

Prelude Therapeutics IND Cleared for Novel Breast Cancer Drug

PremiumCompany Announcements

Prelude Therapeutics IND Cleared for Novel Breast Cancer Drug

1M ago

Prelude Therapeutics receives FDA clearance for PRT13722 IND application

PremiumThe Fly

Prelude Therapeutics receives FDA clearance for PRT13722 IND application

1M ago

Prelude Therapeutics, Inc. (PRLD) Q2 Earnings Cheat Sheet

PremiumPre-EarningsPrelude Therapeutics, Inc. (PRLD) Q2 Earnings Cheat Sheet

2M ago

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

The Fly

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

2M ago

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

The Fly

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

3M ago

Prelude Therapeutics Shareholders Back Leadership and Governance

PremiumCompany Announcements

Prelude Therapeutics Shareholders Back Leadership and Governance

4M ago

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

PremiumThe Fly

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

5M ago

Prelude Therapeutics Launches Phase 1 Trial and Extends Runway

PremiumCompany Announcements

Prelude Therapeutics Launches Phase 1 Trial and Extends Runway

5M ago

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

PremiumThe Fly

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

5M ago

Prelude Therapeutics initiated with a Buy at D. Boral Capital

PremiumThe FlyPrelude Therapeutics initiated with a Buy at D. Boral Capital

6M ago

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

Company Announcements

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

6M ago

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

The Fly

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

6M ago

Prelude Therapeutics Prices Public Offering to Extend Runway

PremiumCompany Announcements

Prelude Therapeutics Prices Public Offering to Extend Runway

6M ago

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

PremiumCompany Announcements

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

6M ago

Prelude Therapeutics presents new preclinical data from PRT13722 study

PremiumThe Fly

Prelude Therapeutics presents new preclinical data from PRT13722 study

6M ago

Prelude Therapeutics Appoints Veteran Oncologist as New CMO

PremiumCompany Announcements

Prelude Therapeutics Appoints Veteran Oncologist as New CMO

6M ago

Prelude Therapeutics announces Charles Morris as chief medical officer

PremiumThe FlyPrelude Therapeutics announces Charles Morris as chief medical officer

6M ago

Prelude Therapeutics management to meet with Citizens

The Fly

Prelude Therapeutics management to meet with Citizens

7M ago

Prelude Therapeutics Establishes New ATM Equity Offering Facility

Company Announcements

Prelude Therapeutics Establishes New ATM Equity Offering Facility

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >